Announced Fri, 29 May · 14:36 IST

Appointment of M/s. KP & Associates, Chartered Accountants as Internal Auditors of the Company for the FY 2026-27

Revenue Growth 20pctPat Growth 25pctAuditor Mid Year ChangeRelated Party TransactionsResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-9.6%1-day move
₹85.95
prior close
₹86.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.4-1.2-1.2+0.5-9.6-10.5-10.6-9.9-9.5-8.7-5.8-6.5
Up moveDown movePending
AI summary

Jeevan Scientific Technology Limited reported strong FY2025-26 results. Standalone revenue grew 23.7% to Rs.5,393.13 lakhs while consolidated revenue increased 31.4% to Rs.6,153.71 lakhs. Standalone PAT jumped 124% to Rs.165.01 lakhs and consolidated PAT rose significantly to Rs.103.33 lakhs from just Rs.5.90 lakhs. The company also allotted 1,61,250 equity shares under the ESOP scheme (exercise price Rs.10 per share, money realized Rs.16.12 lakhs), taking total share capital to Rs.20.08 crore. Additionally, 4,80,000 new stock options were granted to eligible employees. M/s. KP & Associates was appointed as internal auditors for FY 2026-27. Statutory auditors M/s. Pavuluri & Co. issued unmodified opinions on both standalone and consolidated financials. The company also invested Rs.300 lakhs in associate Naya Pharma Private Limited during the year.

Likely market impact

Strong revenue and profit growth demonstrates operational strength. ESOP issuance and new auditor appointment indicate governance updates. The Rs.300 lakh investment in associate company represents a related party transaction requiring shareholder attention.